计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| J276066-5mg |
5mg |
现货 ![]() |
| |
| J276066-10mg |
10mg |
现货 ![]() |
| |
| J276066-25mg |
25mg |
现货 ![]() |
| |
| J276066-50mg |
50mg |
现货 ![]() |
| |
| J276066-100mg |
100mg |
现货 ![]() |
|
| 别名 | 4-[(3-苯氧基苯基)甲基]-1-哌嗪羧酸4-硝基苯酯盐酸盐, |
|---|---|
| 英文别名 | DTXSID401029877 | FT-0700116 | GTPL8606 | 4-nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate | AC-36809 | ZINC ACETATE [INCI] | Q6109295 | AKOS024458308 | T0038 | HY-15250 | BCP23894 | SMR004701690 | JZL-195; JZL 195 | NCGC00346837-01 | 4-[(3-Pheno |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | JZL195 |
| 生化机理 | JZL195 是单酰基甘油脂肪酶 (MAGL) 和脂肪酸酰胺水解酶 (FAAH) 的强效双重抑制剂,MAGL 和 FAAH 是降解内源性大麻素 2-arachidonoylglycerol (2-AG) 和 anandamide (AEA) 的酶,而内源性大麻素 2-arachidonoylglycerol (2-AG) 和 anandamide (AEA) 是大麻素 G 蛋白偶联受体 CB1 和 CB2 的内源性配体。MAGL 的 IC50 值为 2 nM,FAAH 的 IC50 值为 4 nM。研究表明,JZL195 可抑制内源性大麻素水解,并提高体内 2-AG 和 AEA 的水平。 |
| 储存温度 | -20°C储存,干燥 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 酰氧基乙酰水解酶抑制剂;脂肪酸酰胺水解酶抑制剂;单酰甘油脂肪酶抑制剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
JZL195是有效的FAAH和MAGL抑制剂,IC50分别为2 nM和4 nM JZL195 has been used: as a selective inhibitor of endocannabinoid (eCB) clearance enzymes to induce in vivo long-term depression at CA3-CA1 synapses and at prelimbic (PrL)-nucleus accumbens (NAc)synapses, to study the neuroprotective action of eCB to inhibit the action of hydrolytic enzymes that limit eCB activity, to study the effect of 2-linoleoylglycerol (2-LG) on the human CB1 receptor activity as a dual fatty acid amide hydrolase (FAAH)/monoacylglycerol lipase (MAGL) inhibitor to study its dose-related antipruritic effect on the serotonin (5-HT)-induced scratching model |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504770699 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | (4-nitrophenyl) 4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylate |
| INCHI | 1S/C24H23N3O5/c28-24(32-22-11-9-20(10-12-22)27(29)30)26-15-13-25(14-16-26)18-19-5-4-8-23(17-19)31-21-6-2-1-3-7-21/h1-12,17H,13-16,18H2 |
| InChi Key | QNYRAEKLMNDRFY-UHFFFAOYSA-N |
| Smiles | C1CN(CCN1CC2=CC(=CC=C2)OC3=CC=CC=C3)C(=O)OC4=CC=C(C=C4)[N+](=O)[O-] |
| Isomeric SMILES | C1CN(CCN1CC2=CC(=CC=C2)OC3=CC=CC=C3)C(=O)OC4=CC=C(C=C4)[N+](=O)[O-] |
| 分子量 | 433.5 |
| Reaxy-Rn | 20493670 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=20493670&ln= |
| 溶解性 | Soluble in DMSO to 100 mM |
|---|---|
| 分子量 | 433.500 g/mol |
| XLogP3 | 4.300 |
| 氢键供体数Hydrogen Bond Donor Count | 0 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 433.164 Da |
| 单同位素质量Monoisotopic Mass | 433.164 Da |
| 拓扑极表面积Topological Polar Surface Area | 87.800 Ų |
| 重原子数Heavy Atom Count | 32 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 605.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS09 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H400: 对水生生物有剧毒 |
| 预防措施声明 |
P273: 避免释放到环境中。 |
| 1. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL et al.. (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.. Proc Natl Acad Sci USA, 106 (48): (20270-5). [PMID:19918051] |
| 2. Anderson WB, Gould MJ, Torres RD, Mitchell VA, Vaughan CW. (2014) Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model.. Neuropharmacology, 81 (224-30). [PMID:24384256] |
| 3. Sakin YS, Dogrul A, Ilkaya F, Seyrek M, Ulas UH, Gulsen M, Bagci S. (2015) The effect of FAAH, MAGL, and Dual FAAH/MAGL inhibition on inflammatory and colorectal distension-induced visceral pain models in Rodents.. Neurogastroenterol Motil, 27 (7): (936-44). [PMID:25869205] |
| 4. Ghosh S, Kinsey SG, Liu QS, Hruba L, McMahon LR, Grim TW, Merritt CR, Wise LE, Abdullah RA, Selley DE et al.. (2015) Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice.. J Pharmacol Exp Ther, 354 (2): (111-20). [PMID:25998048] |
| 5. Adamson Barnes NS, Mitchell VA, Kazantzis NP, Vaughan CW. (2016) Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model.. Br J Pharmacol, 173 (1): (77-87). [PMID:26398331] |
| 6. Bachovchin DA, Koblan LW, Wu W, Liu Y, Li Y, Zhao P, Woznica I, Shu Y, Lai JH, Poplawski SE et al.. (2014) A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity.. Nat Chem Biol, 10 (8): (656-63). [PMID:24997602] |